ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
EPS (Diluted)
ABL Bio Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
EPS (Diluted)
-₩1.2k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
EPS (Diluted)
₩2k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
EPS (Diluted)
-₩649
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
EPS (Diluted)
₩11.9k
|
CAGR 3-Years
39%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
EPS (Diluted)
₩8.9k
|
CAGR 3-Years
24%
|
CAGR 5-Years
37%
|
CAGR 10-Years
22%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
EPS (Diluted)
₩1.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
44%
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's EPS (Diluted)?
EPS (Diluted)
-1.2k
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's EPS (Diluted) amounts to -1.2k KRW.
What is ABL Bio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-7%
Over the last year, the EPS (Diluted) growth was -1 990%. The average annual EPS (Diluted) growth rates for ABL Bio Inc have been -8% over the past three years , -7% over the past five years .
You don't have any saved screeners yet